Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. (Q47918080)

6 February 2018

title

Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. (English)

1 reference

6 February 2018

0 references

Manfred Ballmann

1

1 reference

6 February 2018

Horst von der Hardt

series ordinal

2

1 reference

6 February 2018

publication date

1 March 2002

1 reference

6 February 2018

Journal of Cystic Fibrosis

published in

1 reference

6 February 2018

volume

1

1 reference

6 February 2018

issue

1

1 reference

6 February 2018

page(s)

35-37

1 reference

6 February 2018

Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2801%2900009-1

7 January 2021

Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2801%2900009-1

7 January 2021

328. Note: The Use of None-Parametric Methods in the Statistical Analysis of the Two-Period Change-Over Design

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2801%2900009-1

7 January 2021

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2801%2900009-1

7 January 2021

Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2801%2900009-1

7 January 2021

Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2801%2900009-1

7 January 2021

Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2801%2900009-1

7 January 2021

Elemental composition of human airway surface fluid in healthy and diseased airways

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2801%2900009-1

7 January 2021

Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2801%2900009-1

7 January 2021

Elemental content of airway surface liquid from infants with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2801%2900009-1

7 January 2021

Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2801%2900009-1

7 January 2021

Salt-independent abnormality of antimicrobial activity in cystic fibrosis airway surface fluid

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2801%2900009-1

7 January 2021

10.1016/S1569-1993(01)00009-1

Identifiers

DOI

1 reference

6 February 2018

PubMed ID

15463808

1 reference

6 February 2018